The HPV vaccine is safe and effective at preventing human papilloma virus, according to the longest investigation ever conducted on the relatively new shot.
While the vaccine has been a success in every study since it came out in the US and the UK in 2006, the medical community has been keenly waiting for some long-term data to show its lingering benefits.
Today, Augusta University’s 10-year study was published in the journal Pediatrics, appearing to confirm the findings in every other short-term report.
The data also supported the view that the vaccine should be administered to both boys and girls from the age of nine years old, despite previously only being offered to girls.
Experts say they hope the findings will help drive up rates of children getting the vaccine, which protects against HPV and therefore HPV-linked cancers such as throat, head, neck, penis, and cervical cancer.